Phio Pharmaceuticals Corp PHIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.04
- Day Range
- $1.02–1.06
- 52-Week Range
- $0.81–4.19
- Bid/Ask
- $1.01 / $1.08
- Shares Outstanding
- 11.62M
- Market Cap
- $11.85M
- Volume/Avg
- 65,039 / 162,298
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
- Website
- https://www.phiopharma.com
Valuation
|
Metric
|
PHIO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.71 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
PHIO
Financial Strength
|
Metric
|
PHIO
|
|---|---|
Quick Ratio | 17.93 |
Current Ratio | 18.32 |
Interest Coverage | — |
Quick Ratio
PHIO
Profitability
|
Metric
|
PHIO
|
|---|---|
Return on Assets (Normalized) | −67.73% |
Return on Equity (Normalized) | −74.07% |
Return on Invested Capital (Normalized) | −74.07% |
Return on Assets
PHIO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@m?XB#& | LOCK|c#X!% | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|xltrFx | LOCK|rcTXX | $70B | |||
| argenx SE ADR
ARGX
| LOCK|%#&vtpX | LOCK|P% | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|b?$MYf% | LOCK|$%Q> | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#@j&WP# | LOCK|wv> | $36B | |||
| Moderna Inc
MRNA
| LOCK|>VqvkW | LOCK|?B | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@qX#!Z%@ | LOCK|#!KP | $25B | |||
| Incyte Corp
INCY
| LOCK|!r$?l& | LOCK|>ZF | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|^dTg?^w | LOCK|&?V | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|&JX<Zjn | LOCK|gfQ | $17B |
United States